Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B

Patent metadata

Field	Value
Publication number	US-10676429-B2
Application number	US-201314423963-A
Country	US
Kind code	B2
Filing date	Aug 28, 2013
Priority date	Aug 28, 2012
Publication date	Jun 9, 2020
Grant date	Jun 9, 2020

Abstract

The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.

First claim

The invention claimed is:

1. A compound of Formula (Ia)

or a stereoisomer or tautomeric form thereof, a pharmaceutically acceptable salt, or a solvate thereof, wherein:
B is a monocyclic 6 membered aromatic ring containing one heteroatom, wherein said heteroatom is N and said 6 membered aromatic ring is optionally substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, C 1 -C 3 alkyl, CN, CFH 2 , CF 2 H and CF 3 ;
R 1 is hydrogen or C 1 -C 3 alkyl;
R 2 is C 1 -C 6 alkyl, C 1 -C 3 alkyl-R 5 , benzyl, C(═O)—R 5 , CFH 2 , CF 2 H, CF 3 or a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, wherein said 3-7 membered saturated ring or C 1 -C 6 alkyl is optionally substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, C 1 -C 4 alkyloxy, oxo, C(═O)—C 1 -C 3 alkyl, C 1 -C 4 alkyl, OH, CN, CFH 2 , CF 2 H and CF 3 ;
each R 4 is independently selected from the group consisting of hydrogen, halo, C 1 -C 4 alkyloxy, C 1 -C 4 alkyl, OH, CN, CFH 2 , CF 2 H, CF 3 and a 3-5 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O and N; and
R 5 is C 1 -C 6 alkyl, CFH 2 , CF 2 H, CF 3 or a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, wherein said 3-7 membered saturated ring is optionally substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, C 1 -C 4 alkyloxy, oxo, C(═O)—C 1 -C 3 alkyl, C 1 -C 4 alkyl, OH, CN, CFH 2 , CF 2 H and CF 3 .

2. A compound as claimed in claim 1 , wherein R 2 is a 6-membered saturated ring, wherein said 6 membered saturated ring is optionally substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, C 1 -C 4 alkyloxy, C(═O)—C 1 -C 3 alkyl, C 1 -C 4 alkyl, OH, CN, CFH 2 , CF 2 H and CF 3.

3. A compound as claimed in claim 1 , wherein R 2 is a 4-7 membered saturated ring containing carbon and one or more oxygen atoms, wherein said 4-7 membered saturated ring is optionally substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, C 1 -C 4 alkyloxy, C(═O)—C 1 -C 3 alkyl, C 1 -C 4 alkyl, OH, CN, CFH 2 , CF 2 H and CF 3 .

4. A compound of Formula (Ia) as claimed in claim 1 , wherein
R 2 is C 1 -C 3 alkyl-R 5 or a 4-7 membered saturated ring consisting of carbon atoms and one or more heteroatoms each independently selected from the group consisting of O or S, said 4-7 membered saturated ring is optionally substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, C 1 -C 4 alkyloxy, oxo, C(═O)—C 1 -C 3 alkyl, C 1 -C 4 alkyl, OH, CN, CFH 2 , CF 2 H and CF 3 , and
R 5 is a 4-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O and S, wherein said 4-7 membered saturated ring is optionally substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, C 1 -C 4 alkyloxy, oxo, C(═O)—C 1 -C 3 alkyl, C 1 -C 4 alkyl, OH, CN, CFH 2 , CF 2 H and CF 3 .

5. A compound as claimed in claim 1 , wherein at least one R 4 is fluoro, C 1 -C 3 alkyl or cyclopropyl.

6. A compound as claimed in claim 1 , wherein one R 4 is the para position and said para R 4 is fluoro, and a second R 4 is in the meta position and said meta R 4 is methyl.

7. A method of treating an HBV infection in a mammal, comprising administering to said mammal a therapeutically effective amount of at least one compound as claimed in claim 1 .

8. A pharmaceutical composition comprising a compound as claimed in claim 1 , and a pharmaceutically acceptable carrier.

9. A product comprising a compound of formula (Ia) as claimed in claim 1 , and another HBV inhibitor, as a combined preparation for simultaneous, separate or sequential use in the treatment of HBV infections.

10. A compound selected from the group consisting of

11. A method of treating an HBV infection in a mammal, comprising administering to said mammal a therapeutically effective amount of at least one compound of Formula (Ia)
or a stereoisomer or tautomeric form thereof, or a pharmaceutically acceptable salt, or a solvate thereof, wherein:
B is a monocyclic 6-membered aromatic ring, containing one heteroatom, wherein said heteroatom is N and said 6-membered aromatic ring is optionally substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, C 1 -C 3 alkyl, CN, CFH 2 , CF 2 H and CF 3;
R 1 is hydrogen or C 1 -C 3 alkyl;
R 2 is selected from the group consisting of C 1 -C 6 alkyl, C 1 -C 3 alkyl-R 5 , benzyl, C(═O)-R 5 , CFH 2 , CF 2 H, CF 3 and a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, wherein said 3-7 membered saturated ring or C 1 -C 6 alkyl is optionally substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, C 1 -C 4 alkyloxy, oxo, C(═O)-C 1 -C 3 alkyl, C 1 -C 4 alkyl, OH, CN, CFH 2 , CF 2 H and CF 3 ;
or R 1 and R 2 together with the nitrogen to which they are attached form a 1,4-dioxa-8-azaspiro[4.5]moiety or a 5-7 membered saturated ring, optionally containing one or more additional heteroatoms each independently selected from the group consisting of O, S and N, wherein said 5-7 membered saturated ring is optionally substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, C 1 -C 4 alkyloxy, oxo, C(═O)-C 1 -C 3 alkyl, C 1 -C 4 alkyl, OH, CN, CFH 2 , CF 2 H and CF 3;
each R 4 is independently selected from the group consisting of hydrogen, halo, C 1 -C 4 alkyloxy, C 1 -C 4 alkyl, OH, CN, CFH 2 , CF 2 H, CF 3 and a 3-5 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O and N; and
R 5 is C 1 -C 6 alkyl, CFH 2 , CF 2 H, CF 3 or a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, wherein said 3-7 membered saturated ring is optionally substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, C 1 -C 4 alkyloxy, oxo, C(═O)-C 1 -C 3 alkyl, C 1 -C 4 alkyl, OH, CN, CFH 2 , CF 2 H and CF 3.

12. A product comprising at least one compound of formula (Ia)

or a stereoisomer or tautomeric form thereof, or a pharmaceutically acceptable salt or a solvate thereof, and another HBV inhibitor, as a combined preparation for simultaneous, separate or sequential use in the treatment of HBV infections, wherein
B is a monocyclic 6-membered aromatic ring, containing one heteroatom, wherein said heteroatom is N and said 6-membered aromatic ring is optionally substituted with one or more substituents each independently selected from the group consisting of hydrogen,

Assignees

• Janssen Sciences Ireland Uc

Inventors

• Vandyck Koen
• Last Stefaan Julien
• Rombouts Geert
• Verschueren Wim Gaston
• Raboisson Pierre Jean-Marie Bernard

Classifications

• A61K31/4468

  having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl · CPC title

• C07D307/22

  Nitrogen atoms not forming part of a nitro radical · CPC title

• C07C2601/08

  the ring being saturated · CPC title

• C07D211/56

  Nitrogen atoms (nitro radicals C07D211/38) · CPC title

• A61K31/4453

  only substituted in position 1, e.g. propipocaine, diperodon · CPC title